Completed PHASE2 INTERVENTIONAL 1-arm NCT00371345

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer

Sponsor: Bristol-Myers Squibb

Conditions Breast Cancer Metastasis

Interventions Dasatinib Dasatinib 100 mg

Updated 7 times since 2017 Last updated: Apr 21, 2011 Started: Dec 31, 2006 Primary completion: Mar 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00371345, this PHASE2 trial focuses on Breast Cancer and Metastasis and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arequipa, Peru , Barcelona, Spain , Boston, United States , Brussels, Belgium , Buenos Aires, Argentina , Chapel Hill, United States , Dijon, France , Haedo, Argentina , Houston, United States , Jacksonville, United States and 10 more locations